Regulus Therapeutics (RGLS) News Today $1.95 +0.04 (+2.09%) Closing price 04:00 PM EasternExtended Trading$1.88 -0.08 (-3.85%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Regulus Therapeutics (NASDAQ:RGLS) Stock Price Crosses Above 200-Day Moving Average - Time to Sell?Regulus Therapeutics (NASDAQ:RGLS) Stock Passes Above Two Hundred Day Moving Average - Here's What HappenedApril 14 at 2:35 AM | marketbeat.comRegulus Therapeutics Inc (RGLS)April 10, 2025 | uk.investing.comRegulus Therapeutics (NASDAQ:RGLS) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell?Regulus Therapeutics (NASDAQ:RGLS) Stock Passes Above 200 Day Moving Average - Time to Sell?April 5, 2025 | marketbeat.comRegulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech SummitApril 2, 2025 | prnewswire.comRegulus Therapeutics Leads The Charge Among 3 Promising Penny StocksMarch 31, 2025 | uk.finance.yahoo.comRegulus upgraded to Overweight from Equal Weight at Wells FargoMarch 29, 2025 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Regulus (RGLS)March 29, 2025 | markets.businessinsider.comRegulus jumps after data update from early-stage trial for kidney disease therapyMarch 28, 2025 | msn.comRegulus Therapeutics (NASDAQ:RGLS) Rating Increased to Overweight at Wells Fargo & CompanyWells Fargo & Company raised shares of Regulus Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price target for the stock from $3.00 to $6.00 in a research report on Thursday.March 28, 2025 | marketbeat.comWells Fargo Upgrades Regulus Therapeutics (RGLS)March 28, 2025 | msn.comRegulus stock surges on positive trial resultsMarch 27, 2025 | za.investing.comRegulus shares surge on Wells Fargo upgrade, clinical updateMarch 27, 2025 | investing.comRegulus Therapeutics (RGLS) Announces Promising Phase 1b Trial ResultsMarch 27, 2025 | gurufocus.comRegulus jumps after data from early-stage trial for kidney disease therapy (update)March 27, 2025 | msn.comRegulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney DiseaseMarch 27, 2025 | benzinga.comRegulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)March 27, 2025 | prnewswire.com4 Best Stocks To Buy Under $5March 20, 2025 | 247wallst.comRegulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right NowMarch 18, 2025 | msn.comRegulus Therapeutics (NASDAQ:RGLS) Given "Buy" Rating at Canaccord Genuity GroupCanaccord Genuity Group restated a "buy" rating and issued a $28.00 target price on shares of Regulus Therapeutics in a research report on Monday.March 18, 2025 | marketbeat.comPromising Developments and Strategic Positioning Drive Buy Rating for Regulus TherapeuticsMarch 17, 2025 | tipranks.comDoes Regulus Therapeutics Have A Long Cash Runway?March 15, 2025 | finance.yahoo.comRegulus Therapeutics' (RGLS) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Regulus Therapeutics in a research report on Friday.March 15, 2025 | marketbeat.comRegulus Therapeutics Reports Positive Trial Results and FinancialsMarch 15, 2025 | tipranks.comRegulus Therapeutics (NASDAQ:RGLS) Issues Earnings Results, Hits EstimatesRegulus Therapeutics (NASDAQ:RGLS - Get Free Report) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.20) EPS for the quarter, hitting analysts' consensus estimates of ($0.20).March 14, 2025 | marketbeat.comRegulus reports Q4 EPS (20c), consensus (22c)March 13, 2025 | markets.businessinsider.comRegulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent UpdatesMarch 13, 2025 | gurufocus.comRegulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent UpdatesMarch 13, 2025 | prnewswire.comRegulus Therapeutics (RGLS) to Release Quarterly Earnings on ThursdayRegulus Therapeutics (NASDAQ:RGLS) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 13, 2025 | marketbeat.comRegulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare ConferenceMarch 4, 2025 | prnewswire.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and five have given a buy rating toMarch 3, 2025 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Regulus Therapeutics in a research report on Wednesday.February 26, 2025 | marketbeat.comRegulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying RecentlyFebruary 21, 2025 | insidermonkey.comRegulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying RecentlyFebruary 21, 2025 | msn.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Recommendation of "Moderate Buy" by AnalystsShares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have isFebruary 6, 2025 | marketbeat.comRegulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | prnewswire.comInsiders Give Up US$8.7k As Regulus Therapeutics Stock Drops To US$1.00February 2, 2025 | finance.yahoo.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Director Purchases $20,786.60 in StockFebruary 1, 2025 | insidertrades.comInsider Buying: Joseph Hagan Acquires 50,000 Shares of Regulus Therapeutics Inc (RGLS)January 31, 2025 | gurufocus.comInsider Buying: David Baltimore Acquires Shares of Regulus Therapeutics Inc (RGLS)January 31, 2025 | gurufocus.comDavid Baltimore Buys 19,610 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) StockRegulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) Director David Baltimore acquired 19,610 shares of the firm's stock in a transaction that occurred on Thursday, January 30th. The shares were bought at an average price of $1.06 per share, for a total transaction of $20,786.60. Following the completion of the purchase, the director now owns 22,169 shares in the company, valued at $23,499.14. This trade represents a 766.31 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.January 31, 2025 | marketbeat.comRegulus Therapeutics Inc. (NASDAQ:RGLS) CEO Buys $54,500.00 in StockRegulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) CEO Joseph P. Hagan bought 50,000 shares of the company's stock in a transaction that occurred on Thursday, January 30th. The shares were acquired at an average cost of $1.09 per share, with a total value of $54,500.00. Following the transaction, the chief executive officer now owns 260,808 shares in the company, valued at approximately $284,280.72. This represents a 23.72 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.January 31, 2025 | marketbeat.comRegulus announces clinical and regulatory updates from its ADPKD programJanuary 31, 2025 | markets.businessinsider.comRegulus Therapeutics Provides Positive Clinical And Regulatory Updates For ADPKD ProgramJanuary 29, 2025 | markets.businessinsider.comRegulus reports progress in ADPKD trial and FDA talksJanuary 29, 2025 | msn.comRegulus stock tumbles 24% amid study, regulatory updatesJanuary 29, 2025 | msn.comRegulus Therapeutics Shares Drop 24% Despite Positive ADPKD Trial DataJanuary 29, 2025 | gurufocus.comRegulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)January 29, 2025 | prnewswire.comRegulus Therapeutics stock hits 52-week low at $1.16January 28, 2025 | msn.comInsider Selling: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insider Sells 31,445 Shares of StockJanuary 16, 2025 | insidertrades.comInsider Selling: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insider Sells 31,445 Shares of StockRegulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) insider Preston Klassen sold 31,445 shares of the firm's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $39,620.70. Following the completion of the sale, the insider now owns 36,055 shares in the company, valued at approximately $45,429.30. This represents a 46.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.January 15, 2025 | marketbeat.com Remove Ads Get Regulus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Email Address RGLS Media Mentions By Week RGLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGLS News Sentiment▼0.220.80▲Average Medical News Sentiment RGLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGLS Articles This Week▼42▲RGLS Articles Average Week Remove Ads Get Regulus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Zenas Biopharma News Rigel Pharmaceuticals News Vanda Pharmaceuticals News Emergent BioSolutions News Verastem News XOMA News Codexis News Sangamo Therapeutics News Lexicon Pharmaceuticals News Ironwood Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RGLS) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regulus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RGLS Stock Free RGLS Stock Alerts